Cannabis News

FDA Submits New Cannabis Products Enforcement Policy For White House Review

Published

3 months ago

March 16, 2026

admin

The Food and Drug Administration (FDA) has proposed a cannabis product enforcement policy to the White House for review on regulatory issues specifically related to CBD.

The Office of Information and Regulatory Affairs (OIRA) of the White House’s Office of Management and Budget (OMB) published a statement on Friday that it received the submission from the FDA, which is under the US Department of Health and Human Services (HHS).

Although the update does not include the text of the proposal now being considered by OIRA, it is titled “Cannabidiol (CBD) Product Compliance and Enforcement Policy.”

The fact that the document comes from the FDA can clarify its content, for example The agency recently missed a Congressional deadline to publish a list of known cannabinoids because federal hemp laws are set to change later this year.

Another possibility raised by industry observers is that it ties into an executive order to reorganize marijuana that President Donald Trump signed in December, which included provisions to provide federal health insurance coverage for CBD to certain patients. But that rulemaking is being facilitated by the Centers for Medicare and Medicaid Services (CMS), which is not listed as the agency that submitted the proposal to OIRA.

Marijuana Moment reached out to HHS and the FDA for comment, but a representative was not immediately available.

As part of the appropriations legislation that Trump signed into law, the 2018 Farm Bill will ban many of the hemp products that were legalized during his first term once again starting in November. The spending measure contained separate provisions, however, for the FDA and other relevant agencies to study the cannabinoid market and develop lists of cannabis ingredients.

After signing the bill, the FDA was given 90 days to publish 1) a list of “all cannabinoids known to the FDA” in cannabis 2) a list of “all cannabinoids of the tetrahydrocannabinol class that the agency believes occur naturally in the plant” and 3) a list of “binoids that have similar effects or may have effects similar to the market. cannabinoids of the tetrahydrocannabinol class”.

It was also tasked with providing the agency with “additional information and specificity” regarding the term “container” in relation to THC serving sizes of hemp product. In the bill, the term is defined as “the inner packaging, container, or container in direct contact with a final hemp-derived cannabinoid product into which the final hemp-derived product is placed for retail sale to consumers, such as a jar, bottle, bag, box, package, can, carton, or cartridge.”

The listings and information were due by February 10, but the FDA missed the deadline.

It is possible, of course, new politics The submission to OIRA is unrelated to the FDA’s mandate to create a list of cannabinoids. Others see it as the next step in expanding federal health insurance coverage, which would make CBD products available to certain patients.

An executive at a hemp company working with CMS on CBD coverage said as much last month The agency has already finalized a rule to allow for federal health insurance coverage. That rule was introduced by Trump under Title III of the Marijuana Controlled Substances Act (CSA).

Mehmet Oz, CMS administrator, spoke about the CBD components of the initiative at the order signing ceremony, with Trump and Robert F. Kennedy Jr. To the HHS secretary for “driving change” and pursuing an agenda based on a “deep passion for research.”

The plan has been to create a pilot program to give eligible patients access to hemp-derived cannabidiol that would be covered by federal health insurance plans, scheduled to launch in April, according to Oz.

While the broader rules for the CBD Medicare pilot program have yet to be released, CMS’ website briefly outlines how it navigates hemp-related issues within the LEAD, Accountable Care Organization (ACO), and Enhancing Oncology Model (EOM) regulatory models.

One outstanding question is about coverage eligibility. As the administrator described in December, it would affect those 65 and older who are eligible for Medicare, but the exact conditions were not specified. There were repeated mentions of chronic pain, particularly in relation to cancer, but the CBD eligibility criteria may include additional conditions.

While CMS issued a previous final rule this past April specifically stipulating that marijuana, as well as CBD derived from federal law hemp, are ineligible For coverage of the Medicare Advantage program and other services, the agency is revising that policy.

CMS already announced some changes as part of a rulemaking process filed late last year, It affects “marketing and communications, drug coverage, enrollment processes, special needs plans and other programming areas.” for the insurance programs it oversees. One of these changes concerned the coverage of cannabidiol.

The proposed rule would change the regulations, which currently say that “cannabis products” cannot be covered. The policy would “prevent coverage of cannabis products that are illegal under applicable state or federal law, including the Food, Drug, and Cosmetic Act.” Because hemp and its derivatives like CBD are federally legal, the change suggests that patients in states where these products are legal can make valid insurance claims to pay for alternative treatment options, as long as the product is federally legal.

Another possibility for new submissions under the OIRA review is that it is unrelated to the FDA mandate or CMS health coverage developments. The FDA has faced scrutiny for years after refusing to enact rules that allow CBD to be legally marketed in the food supply, so there are a number of regulatory issues the proposal could address.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

We don’t really deal with a lot of mites because of our IPM program

Published

11 hours ago

June 9, 2026

admin

Flora Farms Pest Management Program it is built to reduce to nothing depending on the harvestso the plant ends up clean. Luke Allenbrand, Flora Farms’ crop leader, leads an integrated pest management program that focuses on prevention. “We don’t honestly deal with a lot of mites because of the IPM program, because of the predatory mites that we’ve put down as a precaution,” says Luke. “It allows us to have a much cleaner garden in the back half.” Preventative work keeps spray volumes relatively low because the curative side of the program rarely needs to be heavy.

“Actually, we are at the lowest number of these sprays that we have. The milliliters that we are using are numbers that do not exist to be a prevention,” says Luke. “But as soon as you see an uptick of those mites or anything, we bring it up to a therapeutic amount, which is still a small milliliter. And as long as you’re on a fast track with it, you see them disappear within 10 days.” The targets are spider mites, which feed on the plant’s THC and terpene production and degrade the flower.

Tested solutions
The three products used by the company are derived from agricultural and food use. “We actually apply about three insecticides that are very common around the agricultural and food grade of these products, using a suite of IPM, Venerate and Grandevo, insecticides that will deal with these mites,” says Luke. The application is intermittent rather than constant. “We usually use a 5-day spray cycle so we can have rest periods in between, so it’s not just a consistent density of that spray,” says Luke. He sees progress against mites in the gaps between the successions.

However, at some point, the spraying stops. “We finish the spray cycle by day 40. We usually don’t want to spray anywhere after day 40. At that point, you’re going to damage the product,” says Luke. “And at that point, we’ll put predatory mites in. It really helps us get to that final push point by day 59, 60 of that harvest. So we actually have a lot less of our spray in that late period. So it’s a much better tasting product.” Predatory mites take over the job of spraying, leaving nothing on the flower.

Biological control
Biological control has two forms. “We usually use them, they’re called crazy mites, and honestly, it’s crazy to see,” says Luke. “Actually, I’ve seen some of the ones in a close-up photo kill a bug, some of the cocoons actually drive away, and even attack the spider mites themselves. Very beneficial. Callias are also slow. They’re little bags that we hang on plants and they’re very beneficial to us.” Different predators work at different speeds, which is why the program runs more than one.

Missouri’s testing regime is the context in which growers operate. Each plant is tested for pest control chemicals and must pass before the product goes ahead. “Other crops and other black market shops or smoke shops in Missouri don’t have to worry about the testing we have to do,” Luke says. “Everything we use here is natural. Each of our pest management is a lot of essential oils that fight these mites. Everything we would put on a plant is food grade.” The test covers foreign chemicals, heavy metals, and anything else that an unregulated supply should never consider.

The whole arc is from biology to chemistry and back to biology. “We go from predatory mites to a food-grade spray regimen, and then back to predatory mites at the end. That way, these plants will have time to finish with no chemicals, nothing,” says Luke. “The rest of that life cycle, about 15 to 20 days, is the most natural it will have. No spraying at all during that, just to push predatory mites off that end, so there’s no residual mite damage on those plants.”

For more information:
Flower Farms
florafarmsmo.com

Cannabis News

California Bill To Legalize Marijuana Dispensary Drive-Thru Windows Advances In Senate After Clearing Full Assembly

Published

12 hours ago

June 9, 2026

admin

It has been passed by a California Senate committee and passed by the Assembly bill that would allow marijuana dealers to offer car windows to serve customers.

The measure, which cleared the Senate Business, Careers and Economic Development Committee on a 7-3 vote Monday, says licensed cannabis retailers and micro-businesses with storefronts can sell marijuana products “in a motor vehicle to a customer in a drive-through located on the premises.”

Under Assemblywoman Gail Peller’s (D) AB 2697, cannabis businesses would need permission from the local jurisdictions in which they operate to add a drive-thru.

The sponsor told committee members before the final vote that the bill will “expand access to legal cannabis products while strengthening our ability to compete with the illegal market.”

Annie Aubrey of Chuck’s Wellness Center, a retailer in Placerville, testified that the legislation is “about improving access.”

“A large portion of our customers use cannabis as medicine, including seniors, veterans and people living with chronic conditions that affect mobility, the population that this regulated system seeks to serve,” he said. “For many, even simple tasks like getting out of a vehicle or navigating a retail space can be physically difficult or prohibitive…A drive-thru option removes that barrier, giving patients and consumers access to what they need in a way that’s dignified and consistent with their healthcare needs.”

Amy O’Gorman Jenkins of the California Cannabis Operators Association said the legislation will provide “operational flexibility” in a highly regulated system.

“It doesn’t expand who can access cannabis,” he said. “It allows retailers, with local approval, to serve existing patients and customers more efficiently.”

Jenkins also argued that this measure could improve security.

“Currently, road traction transactions are already allowed. This means that workers regularly have to leave a safe premises while transporting the product, and sometimes they have to deposit cash in parking lots,” he said. “AB 2697 provides an additional mechanism for obtaining product, but requires a fixed and secure transaction point, keeping employees inside and reducing exposure to theft.”

Pellerin, the bill’s sponsor, previously said that “California cannabis retailers lack a common and accessible transaction channel for consumers that so many other retailers in California offer, including fast food, pharmacies, banks and even liquor stores.”

“Cannabis consumers with mobility issues or other disabilities have limited options for obtaining cannabis without having to get out of their vehicles. And while home delivery is legal, there are restrictions on service areas,” he said. “Allowing cannabis sellers to add a secure ride option, if allowed by their local jurisdiction, will improve the consumer experience, increase the security of cannabis sellers and help expand California’s legal cannabis market.”

The California Association of Narcotics Officers opposes the proposal, however, as a representative, Ryan Sherman, testified that it would make it more difficult for dispensary workers to check the IDs of customers who are of legal age or to spot signs of current intoxication at drive-thru windows.

“This bill prioritizes speed of sale over public safety while undermining existing protections designed to prevent illegal sales and protect public safety,” he argued.

Under current policy during the COVID pandemic, dispensaries can already offer street pickup.

The invoice that moving forward in the legislature would mandate that auto sales “be made through a fixed panel security window with a security drawer or similar secure transfer mechanism that is part of a building located within the premises.”

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

California regulators recently approved emergency rule changes to the state’s marijuana licensing process. to make it easier for companies to receive benefits In line with the Trump administration’s latest move to federally regulate medical cannabis.

While Gov. Gavin Newsom (D) recently He took credit for helping lead the state’s push to legalize marijuana and discussed his limited experience with cannabis use.

In October, however, Newsom vetoed a bill that would have It allowed micro-marijuana companies to ship medicinal cannabis directly to patients Through common carriers like FedEx and UPS, he said the proposal would be “too burdensome and complex to manage.”

Newsom signed a bill earlier this month streamlining research into marijuana and psychedelics.

In September, the governor also signed a measure pause on the recent tax increase on marijuana products.

Separately, the state attorney general says Indian tribes cannot independently participate in the marijuana trade with licensed cannabis businesses without obtaining their own commercial license from state officials.

California officials have recently been rewarded nearly $30 million in grants for marijuana-focused academic research projects.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Concert Series Specials launched for state medical cannabis patients

Published

1 day ago

June 8, 2026

admin

Post Dispensary, Kentucky’s first medical cannabis dispensary, is connecting with patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Madisonville, Hopkinsville and surrounding areas by aligning unique specials with the region’s summer concert calendar. Located at 300 N Main St. in Beaver Dam, minutes from major highways connecting these vibrant cities.

This summer, The Post Dispensary is offering special pricing and incentives for Concert Series Events at the Beaver Dam Amphitheater, SPARKS in the Park 4th of July celebration and surrounding events, such as Owensboro’s ROMP Festival (June 24-27, 2026). Patients can stop by before or after shows for big savings.

“We’re more than just a booty,” said a dispensary representative. “From Owensboro’s world-class ROMP Festival to Beaver Dam’s Amphitheater events, we’re making it convenient and budget-friendly for patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Hartford and beyond to combine our love of music with compassionate care and an affordable product.”

The Post Dispensary hosts regular Patient Guidance events on the second Saturday of every month. These units have professionals on hand to assess patients and issue written certificates at low cost, application support and expert consultations in a welcoming environment. The next Patient Drive aligns perfectly with summer travel patterns, making it easy for patients from Owensboro, Bowling Green, Elizabethtown, Madisonville, Henderson, Madisonville and surrounding towns to plan a trip to Beaver Dam that combines care with community and entertainment.

For more information:
Post-Dispensary
thepostdispensary.com/